Human proteinase molecules

Details Human proteinase molecules Human proteinase molecules

2001-03-08

2003-09-30

Huff, Sheela (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C435S007100

Reexamination Certificate

active

06627605

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of human proteinase molecules and to the use of these sequences in the diagnosis and treatment of cancer and immune disorders.
BACKGROUND OF THE INVENTION
Proteolytic processing is an essential component of normal cell growth, differentiation, remodeling, and homeostasis. The cleavage of peptide bonds within cells is necessary for the maturation of precursor proteins to their active form, the removal of signal sequences from targeted proteins, the degradation of incorrectly folded proteins, and the controlled turnover of peptides within the cell.
Proteases participate in apoptosis, antigen presentation, inflammation, tissue remodeling during embryonic development, wound healing, and normal growth. They are necessary components of bacterial, parasitic, and viral invasion and replication within a host. Four principal categories of mammalian proteases have been identified based on active site structure, mechanism of action, and overall three-dimensional structure (Beynon and Bond (1994)
Proteolytic Enzymes: A Practical Approach
, Oxford University Press, New York N.Y., pp. 1-5).
The serine proteases (SPs) are a large family of proteolytic enzymes that include the digestive enzymes, trypsin and chymotrypsin; components of the complement cascade and of the blood-clotting cascade; and enzymes that control the degradation and turnover of macromolecules of the extracellular matrix. SPs are so named because of the presence of a serine residue found in the active catalytic site for protein cleavage. The active site of all SP is composed of a triad of residues including the aforementioned serine, an aspartate, and a histidine residue. SPs have a wide range of substrate specificities and can be subdivided into subfamilies on the basis of these specificities. The main sub-families are trypases which cleave after arginine or lysine; aspases which cleave after aspartate; chymases which cleave after phenylalanine or leucine; metases which cleavage after methionine; and serases which cleave after serine.
The SPs are secretory proteins containing N-terminal signal peptides which export the immature protein across the endoplasmic reticulum prior to cleavage (von Heijne (1986) Nuc Acid Res 14:5683-5690). Differences in these signal sequences provide one means of distinguishing individual SPs. Some SPs, particularly the digestive enzymes, exist as inactive precursors or preproenzymes and contain a leader or activation peptide on the C-terminal side of the signal peptide. This activation peptide may be 2-12 amino acids in length and extend from the cleavage site of the signal peptide to the N-terminus of the active, mature protein. Cleavage of this sequence activates the enzyme. This sequence varies in different SPs according to the biochemical pathway and/or its substrate (Zunino et al. (1990) J Immunol 144:2001-2009; Sayers et al. (1994) J Immunol 152:2289-2297).
Cysteine proteases are involved in diverse cellular processes ranging from the processing of precursor proteins to intracellular degradation. Mammalian cysteine proteases include lysosomal cathepsins and cytosolic calcium activated proteases, cilpains. Cysteine proteases are produced by monocytes, macrophages and other cells of the immune system which migrate to sites of inflammation and in their protective role secrete various molecules to repair damaged tissue. These cells may overproduce the same molecules and cause tissue destruction in certain disorders. In autoimmune diseases such as rheumatoid arthritis, the secretion of the cysteine protease, cathepsin C, degrades collagen, laminin, elastin and other structural proteins found in the extracellular matrix of bones. The cathepsin family of lysosomal proteases includes the cysteine proteases; cathepsins B, H, K, L, O2, and S; and the aspartyl proteases; cathepsins D and E. Various members of this endosomal protease family are differentially expressed. Some, such as cathepsin D, have a ubiquitous tissue distribution while others, such as cathepsin L, are found only in monocytes, macrophages, and other cells of the immune system.
Abnormal regulation and expression of cathepsins has been implicated in various inflammatory disease states. In cells isolated from inflamed synovia, the mRNA for stromelysin, cytokines, TIMP-1, cathepsin, gelatinase, and other molecules is preferentially expressed. Expression of cathepsins L and D is elevated in synovial tissues from patients with rheumatoid arthritis and osteoarthritis. Cathepsin L expression may also contribute to the influx of mononuclear cells which exacerbate the destruction of the rheumatoid synovium (Keyszer (1995) Arthritis Rheum 38:976-984). The increased expression and differential regulation of the cathepsins is linked to the metastatic potential of a variety of cancers and may be of therapeutic and prognostic interest (Chambers et al. (1993) Crit Rev Oncog 4:95-114).
Cysteine proteases are characterized by a catalytic domain containing a triad of amino acid residues similar to that found in serine proteases. A cysteine replaces the active serine residue. Catalysis proceeds via a thiol ester intermediate and is facilitated by the side chains of the adjacent histidine and aspartate residues.
Aspartic proteases include bacterial penicillopepsin, mammalian pepsin, renin, chymosin, cathepsins D and E, and certain fungal proteases. The characteristic active site residues of aspartic proteases are a pair of aspartic acid residues, such as asp33 and asp213 in penicillopepsin. Aspartic proteases are also called acid proteases because the optimum pH for activity is between 2 and 3. In this pH range, only one of the aspartate residues is ionized. A potent inhibitor of aspartic proteases is the hexapeptide, pepstatin, which in the transition state resembles a normal substrate of the enzyme.
Metalloproteases use zinc as an active site component and are most notably represented in mammals by the exopeptidases, carboxypeptidase A and B, and the matrix metalloproteases, collagenase, gelatinase, and stromelysin. Carboxypeptidases A and B are exopeptidases of similar structure and active sites. Carboxypeptidase A, like chymotrypsin, prefers hydrophobic C-terminal aromatic and aliphatic side chains, whereas carboxypeptidase B is directed toward basic arginine and lysine residues. The matrix-metalloproteases are secreted by connective tissue cells and play an important role in the maintenance and function of the basement membrane and extracellular matrix. A naturally occurring inhibitor of metalloproteases, tissue inhibitor of metalloproteases (TIMP), has been shown to prevent the invasion of tumor cells through basement membrane, in vitro, indicating the importance of these enzymes in cell invasion processes such as tumor metastasis and the inflammatory response (Mignatti et al. (1986) Cell 47:487-498).
Protease inhibitors play a major role in the regulation of the activity and effect of proteases. They have been shown to control pathogenesis in animal models of proteolytic disorders (Murphy (1991) Agents Actions Suppl 35:69-76). In particular, low levels of the cystatins, low molecular weight inhibitors of the cysteine proteases, seem to be correlated with malignant progression of tumors (Calkins et al. (1995) Biol Biochem Hoppe Seyler 376:71-80). The balance between levels of cysteine proteases and their inhibitors is also significant in the development of disorders. Specifically, increases in cysteine protease levels, when accompanied by reductions in inhibitor activity, are correlated with increased malignant properties of tumor cells and the pathology of arthritis and immunological diseases in humans.
The discovery of new human proteinase molecules and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis and treatment of cancer and immune disorders.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, human proteinase molecules, referred to collectively as “HPRM” and

Affiliated with

Also associated with

Rating

Human proteinase molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human proteinase molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human proteinase molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3035934